Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg

NCT05569239 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

2850

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: OVX836 480µg
BIOLOGICAL: Saline Solution

Sponsor

Osivax